Kits and assays remain an important growth opportunity for Abcam, with an estimated market size of approximately $500 million for research use. These kits contain all the reagents researchers need to run an experiment and can save considerable time.
We are investing and innovating to move our market-leading antibodies into these products as quickly as possible and at the same time we are raising awareness of these products amongst our consumer base. In the last year we created new products using our recombinant antibody and FirePlex® assay technologies including high-throughput assays to address new customer needs. Overall, we have introduced approximately 400 new immunoassay products during the year, including matched antibody pairs, singleplex immunoassays (SimpleStep ELISA®), and multiplex immunoassays using the FirePlex® particle platform.
At the same time, we have established supply agreements with several leading instrument partners as we work to expand the availability of Abcam’s differentiated antibody content to the widest population of scientists, across the broadest range of platforms.
Jordan L Plieskatt
Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University, USA
Common to Southeast Asia is a small flatworm that you can pick up from eating raw or undercooked fish. Infection with this parasite will predispose you to a cancer of the bile ducts.
Jordan had been looking at microRNA (miRNA) in blood samples for biomarkers to diagnose this cancer. FirePlex® allowed Jordan to evaluate miRNA from small samples faster and more cost-effectively than traditional methods which require large samples and are tricky to run. It has helped him identify a useful biomarker for this cancer, with the potential for patients to get earlier clinical treatment through earlier diagnosis. FirePlex® looks set to help with the ongoing development of an affordable diagnostic for this disease and other similar infection-related cancers.